These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19373249)

  • 21. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes.
    Li P; Zhu D
    J Diabetes; 2024 May; 16(5):e13544. PubMed ID: 38664885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes.
    Thilagavathi R; Hosseini-Zare MS; Malini M; Selvam C
    Chem Biol Drug Des; 2022 Feb; 99(2):247-263. PubMed ID: 34714587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule glucokinase activators as novel anti-diabetic agents.
    Leighton B; Atkinson A; Coghlan MP
    Biochem Soc Trans; 2005 Apr; 33(Pt 2):371-4. PubMed ID: 15787609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists.
    Ren Y; Li L; Wan L; Huang Y; Cao S
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):606-615. PubMed ID: 35067153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Advances in the study of glucokinase and small molecule glucokinase activators].
    Li YQ; Feng ZQ; Song HR; Guo YS; Guo ZR
    Yao Xue Xue Bao; 2006 May; 41(5):390-4. PubMed ID: 16848312
    [No Abstract]   [Full Text] [Related]  

  • 27. Glucokinase, glucose homeostasis, and diabetes mellitus.
    Matschinsky FM
    Curr Diab Rep; 2005 Jun; 5(3):171-6. PubMed ID: 15929862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicine. Drug deals diabetes a one-two punch.
    Couzin J
    Science; 2003 Jul; 301(5631):290. PubMed ID: 12869732
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.
    Baker DJ; Atkinson AM; Wilkinson GP; Coope GJ; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1629-41. PubMed ID: 24772483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
    Guertin KR; Grimsby J
    Curr Med Chem; 2006; 13(15):1839-43. PubMed ID: 16787225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from glucokinase activators: the problem of declining efficacy.
    Agius L
    Expert Opin Ther Pat; 2014 Nov; 24(11):1155-9. PubMed ID: 25266490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770.
    Tilley JW
    Expert Opin Ther Pat; 2009 Apr; 19(4):549-53. PubMed ID: 19441933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism.
    Li YG; Ji DF; Zhong S; Lin TB; Lv ZQ
    Chem Biol Interact; 2015 Jan; 225():70-9. PubMed ID: 25446853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.
    Lloyd DJ; St Jean DJ; Kurzeja RJ; Wahl RC; Michelsen K; Cupples R; Chen M; Wu J; Sivits G; Helmering J; Komorowski R; Ashton KS; Pennington LD; Fotsch C; Vazir M; Chen K; Chmait S; Zhang J; Liu L; Norman MH; Andrews KL; Bartberger MD; Van G; Galbreath EJ; Vonderfecht SL; Wang M; Jordan SR; Véniant MM; Hale C
    Nature; 2013 Dec; 504(7480):437-40. PubMed ID: 24226772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.
    Filipski KJ; Pfefferkorn JA
    Expert Opin Ther Pat; 2014 Aug; 24(8):875-91. PubMed ID: 24821087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
    Bonadonna RC; Heise T; Arbet-Engels C; Kapitza C; Avogaro A; Grimsby J; Zhi J; Grippo JF; Balena R
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5028-36. PubMed ID: 20739378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.
    Grewal AS; Lather V; Charaya N; Sharma N; Singh S; Kairys V
    Curr Pharm Des; 2020; 26(21):2510-2552. PubMed ID: 32286938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.
    Pfefferkorn JA
    Expert Opin Drug Discov; 2013 Mar; 8(3):319-30. PubMed ID: 23289965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
    Zager MG; Kozminski K; Pascual B; Ogilvie KM; Sun S
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):127-39. PubMed ID: 24578187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.